nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Edema cerebral—Carmustine—lymphatic system cancer	0.0973	0.0973	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Mechlorethamine—lymphatic system cancer	0.0681	0.0681	CcSEcCtD
Cisatracurium Besylate—Brain oedema—Carmustine—lymphatic system cancer	0.0526	0.0526	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Fludarabine—lymphatic system cancer	0.037	0.037	CcSEcCtD
Cisatracurium Besylate—Trauma—Bleomycin—lymphatic system cancer	0.0362	0.0362	CcSEcCtD
Cisatracurium Besylate—Hypoxemia—Methotrexate—lymphatic system cancer	0.0347	0.0347	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Carmustine—lymphatic system cancer	0.0282	0.0282	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Vincristine—lymphatic system cancer	0.027	0.027	CcSEcCtD
Cisatracurium Besylate—Wheezing—Bleomycin—lymphatic system cancer	0.0167	0.0167	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Teniposide—lymphatic system cancer	0.0165	0.0165	CcSEcCtD
Cisatracurium Besylate—Injury—Bleomycin—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Methotrexate—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Cisatracurium Besylate—Flushing—Teniposide—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Cisatracurium Besylate—Injury—Carmustine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—lymphatic system cancer	0.011	0.011	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Bleomycin—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Cisatracurium Besylate—Hypertension—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Vincristine—lymphatic system cancer	0.00991	0.00991	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Carmustine—lymphatic system cancer	0.00963	0.00963	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00954	0.00954	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Teniposide—lymphatic system cancer	0.00931	0.00931	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Vincristine—lymphatic system cancer	0.00919	0.00919	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00916	0.00916	CcSEcCtD
Cisatracurium Besylate—Hypotension—Teniposide—lymphatic system cancer	0.00892	0.00892	CcSEcCtD
Cisatracurium Besylate—Convulsion—Fludarabine—lymphatic system cancer	0.0089	0.0089	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Teniposide—lymphatic system cancer	0.00851	0.00851	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00839	0.00839	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00822	0.00822	CcSEcCtD
Cisatracurium Besylate—Rash—Mechlorethamine—lymphatic system cancer	0.00816	0.00816	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00815	0.00815	CcSEcCtD
Cisatracurium Besylate—Flushing—Bleomycin—lymphatic system cancer	0.00803	0.00803	CcSEcCtD
Cisatracurium Besylate—Urticaria—Teniposide—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Cisatracurium Besylate—Erythema—Bleomycin—lymphatic system cancer	0.00753	0.00753	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Fludarabine—lymphatic system cancer	0.00748	0.00748	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00709	0.00709	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Cisatracurium Besylate—Flushing—Carmustine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Cisatracurium Besylate—Pruritus—Teniposide—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Cisatracurium Besylate—Erythema—Carmustine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Vincristine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00615	0.00615	CcSEcCtD
Cisatracurium Besylate—Erythema—Mitoxantrone—lymphatic system cancer	0.00611	0.00611	CcSEcCtD
Cisatracurium Besylate—Rash—Teniposide—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Teniposide—lymphatic system cancer	0.00601	0.00601	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fludarabine—lymphatic system cancer	0.00593	0.00593	CcSEcCtD
Cisatracurium Besylate—Hypotension—Bleomycin—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Cisatracurium Besylate—Convulsion—Carmustine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Cisatracurium Besylate—Hypertension—Carmustine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Bleomycin—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Cisatracurium Besylate—Convulsion—Vincristine—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vincristine—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mitoxantrone—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Cisatracurium Besylate—Rash—Fludarabine—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fludarabine—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mitoxantrone—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Carmustine—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Vincristine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Cisatracurium Besylate—Hypotension—Carmustine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Cisatracurium Besylate—Urticaria—Bleomycin—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Cisatracurium Besylate—Hypotension—Vincristine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Carmustine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mitoxantrone—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Cisatracurium Besylate—Pruritus—Bleomycin—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Cisatracurium Besylate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Rash—Bleomycin—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Bleomycin—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Cisatracurium Besylate—Rash—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Cisatracurium Besylate—Rash—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Rash—Mitoxantrone—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
